Constructing Chimeric Antigen for Precise Screening of HTLV-I Infection
Abstract
Individual preparation of two human T-cell lymphotropic virus type I (HTLV-I) diagnostic GST fused peptides (MTA-1 and GD21) is time-consuming and expensive. The aim of this study was to design a novel single chimeric antigen (SCA) to obviate separate expression of proteins and reduce the cost of reagent preparation.Structural protein fragments, including immunodominant B cell linear epitopes, were selected and different SCAs were designed. Tertiary structure, epitope exposure, solubility and stability were calculated for each SCA and compared with each other. The synthetic DNA encoding the interested SCA was sub-cloned into pET32a expression vector, expressed as a soluble form in Escherichia coli BL21 (DE3) cells and purified under native condition using affinity chromatography.The SDS-PAGE results indicated that thioredoxin-fused SCA was successfully expressed as a soluble form in E. coli BL21 (DE3) cells. The results of ELISA confirmed that SCA reacted with anti-HTLV-I antibodies in a concentration-dependent manner.Our results indicated that the designed SCA may be a good candidate for the screening of HTLV-I carriers with antigen–antibody-based tests.
1. Dantas L, Netto E, Glesby MJ, Carvalho EM, Machado P.Dermatological manifestations of individuals infected with human T cell lymphotropic virus type I (HTLV-I). Int J Dermatol 2014; 53(9):1098-102.
2. O'Brien SF, Goldman M, Scalia V, Yi QL, Fan W, Xi G, et al. The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors. Transfus Med 2013; 23(5):358-66.
3. Sadeghian MH, Keramati MR, Ayatollahi H, Feizabadi AS, Tehranaian F, Shakibyee H. Is there any relationship between expressions of minor blood group antigens with HTLV-I infection? Transfus Apher Sci 2012; 47(2):151-4.
4. Qayyum S, Choi JK. Adult T-cell leukemia/lymphoma.Arch Pathol Lab Med 2014; 138(2):282-6.
5. Lefrere JJ. [Human T-lymphotropic virus type I (HTLV-I):risk of transmission with transfusion]. Presse Med 2000;29(20):1134-8.
6. Yoshimitsu M, White Y, Arima N. Prevention of human T- cell lymphotropic virus type 1 infection and adult T-cell leukemia/lymphoma. Recent Results Cancer Res 2014;193:211-25.
7. Moreno C, Balangero M, Barbas MG, Cudola A, Gallego S. [Serological diagnosis of HTLV-1/2: combination of screening assays to define the serological status in blood donors]. Rev Argent Microbiol 2013; 45(3):165-8.
8. Berini CA, Susana Pascuccio M, Bautista CT, Gendler SA, Eirin ME, Rodriguez C, et al. Comparison of four commercial screening assays for the diagnosis of human T-cell lymphotropic virus types 1 and 2. J Virol Methods 2008; 147(2):322-7.
9. Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J 1996; 10(1):49-56.
10. Hernández M, Selles MaE, Pozo Peña L, Gómez I,Melchor A. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation. Biochem Biophys Res Commun 2000;276(3):1085-8.
11. Hernandez Marin M, Marquez Bocalandro Y, Vallejo RV, Rodriguez Tanty C, Higginson Clark D, Pozo Pena L, et al. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection. Prep Biochem Biotechnol 2003; 33(1):29-38.
12. Rudolph DL, Coligan JE, Lal RB. Detection of antibodies to trans-activator protein (p40taxI) of human T-cell lymphotropic virus type I by a synthetic peptide-based assay. Clin Diagn Lab Immunol 1994; 1(2):176-81.
13. Hernández Marin M, Castellanos Pentón P, Márquez Bocalandro Y, Pozo Peña L, Dıaz Navarro J, Javier González López L. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus. Biochem Biophys Res Commun 2001; 289(1):1-6.
14. Sundaram R, Beebe M, Kaumaya PT. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1. J Pept Res 2004;63(2):132-40.
15. Marin MH, Rodriguez-Tanty C, Higginson-Clarke D, Bocalandro YM, Pena LP. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus. Biochem Biophys Res Commun 2005; 336(3):983-6.
16. Frangione-Beebe M, Albrecht B, Dakappagari N, Rose RT, Brooks CL, Schwendeman SP, et al. Enhanced immunogenicity of a conformational epitope of human T- lymphotropic virus type 1 using a novel chimeric peptide. Vaccine 2000; 19(9-10):1068-81.
17. Yamada K, Kuroda N, Washitani Y, Shiraki H, Maeda Y. Enzyme immunoassay with synthetic peptides to detect anti-HTLV-I antibodies. Clin Chem 1992;38(5):699-703.
18. Robinson CR, Sauer RT. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci U S A 1998;95(11):5929-34.
19. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22(7):346-53.
20. Burgess-Brown NA, Sharma S, Sobott F, Loenarz C, Oppermann U, Gileadi O. Codon optimization can improve expression of human genes in< i> Escherichia coli</i>: A multi-gene study. Protein Expr Purif 2008;59(1):94-102.
21. Upadhyay AK, Singh A, Mukherjee KJ, Panda AK.Refolding and purification of recombinant L-asparaginase from inclusion bodies of E. coli into active tetrameric protein. Front Microbiol 2014; 5:486.
22. Sorensen HP, Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 2005; 4(1):1.
23. Cressey R, Pimpa S, Chewaskulyong B, Lertprasertsuke N, Saeteng S, Tayapiwatana C, et al. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients. BMC Biotechnol 2008; 8:16.
24. Valtanen S, Roivainen M, Hovi T. Problems with biotin- labelled virions as probes in poliovirus-specific mu- capture-IgM assays. J Clin Virol 1999; 14(1):17-23.
25. Lang D, Hinderer W, Rothe M, Sonneborn HH, Neipel F, Raab M, et al. Comparison of the immunoglobulin-G- specific seroreactivity of different recombinant antigens of the human herpesvirus 8. Virology 1999; 260(1):47-54.
26. Klein M, Kotz A, Bernardo K, Kronke M. Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein. J Clin Microbiol 2003; 41(5):1957-62.
| Files | ||
| Issue | Vol 14, No 4 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Antigenicity Chimeric protein ELISA HTLV-I | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
